Quick Answer
Cytek Biosciences, Inc. reported Total Revenue of $201.49 million for fiscal year 2025.
Cytek Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $201.49M +0.5% |
$200.45M +3.9% |
$193.01M +17.7% |
$164.04M +28.2% |
$127.95M +37.8% |
$92.84M |
| Revenue (ASC 606) | $201.49M +0.5% |
$200.45M +3.9% |
$193.01M +17.7% |
$164.04M +28.2% |
$127.95M +37.8% |
$92.84M |
| Net Income | — | — | — | $2.48M -17.9% |
$3.03M -84.4% |
$19.41M |
| Total Assets | $461.54M -7.6% |
$499.50M +1.0% |
$494.46M -4.8% |
$519.48M +12.1% |
$463.31M +110.6% |
$219.98M |
| Cash and Equivalents | $90.85M -8.0% |
$98.72M -41.0% |
$167.30M -43.6% |
$296.60M -18.7% |
$364.62M +120.7% |
$165.23M |
| Stockholders Equity | $341.74M -13.6% |
$395.74M +0.7% |
$393.06M -7.6% |
$425.55M +5.0% |
$405.38M +2629.2% |
-$16.03M -138.4% |
| R&D Expense | $36.47M -7.4% |
$39.40M -10.8% |
$44.15M +26.7% |
$34.86M +42.6% |
$24.44M +78.5% |
$13.69M |
| Operating Income | -$40.38M -96.8% |
-$20.52M +26.3% |
-$27.84M -1443.5% |
-$1.80M -119.7% |
$9.16M -33.0% |
$13.66M |
| Gross Profit | $104.46M -6.0% |
$111.11M +1.5% |
$109.43M +8.4% |
$100.97M +27.6% |
$79.14M +53.1% |
$51.71M |
| Shares Outstanding | 128.55M -0.5% |
129.21M -1.2% |
130.71M -3.4% |
135.37M +1.2% |
133.75M +328.1% |
31.24M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $52.29M | +1.5% | +14.7% |
| Revenue (ASC 606) | September 30, 2025 | $52.29M | +1.5% | +14.7% |
| Net Income | June 30, 2023 | -$4.39M | -525.1% | +35.5% |
| Total Assets | September 30, 2025 | $494.92M | +0.8% | +0.3% |
| Cash and Equivalents | September 30, 2025 | $93.28M | -42.5% | +23.6% |
| Stockholders Equity | September 30, 2025 | $378.57M | -1.8% | +0.3% |
| R&D Expense | September 30, 2025 | $8.96M | -9.4% | +1.5% |
| Operating Income | September 30, 2025 | -$9.19M | -116.4% | +13.5% |
| Gross Profit | September 30, 2025 | $27.55M | -5.0% | +15.4% |
| Shares Outstanding | September 30, 2025 | 127.86M | -1.5% | +0.5% |
- Cytek Biosciences, Inc. reported Total Revenue of $201.49 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed an increase of +0.5% in Total Revenue compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Revenue (ASC 606) of $201.49 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed an increase of +0.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Net Income of $2.48 million for fiscal year 2022.
- Cytek Biosciences, Inc. showed a decrease of -17.9% in Net Income compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Total Assets of $461.54 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -7.6% in Total Assets compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Cash and Equivalents of $90.85 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -8.0% in Cash and Equivalents compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Stockholders Equity of $341.74 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -13.6% in Stockholders Equity compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported R&D Expense of $36.47 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -7.4% in R&D Expense compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Operating Income of -$40.38 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -96.8% in Operating Income compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Gross Profit of $104.46 million for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -6.0% in Gross Profit compared to the prior fiscal year.
- Cytek Biosciences, Inc. reported Shares Outstanding of 128.55 million shares for fiscal year 2025.
- Cytek Biosciences, Inc. showed a decrease of -0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: